These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23460714)

  • 1. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
    Argiris A; Ghebremichael M; Gilbert J; Lee JW; Sachidanandam K; Kolesar JM; Burtness B; Forastiere AA
    J Clin Oncol; 2013 Apr; 31(11):1405-14. PubMed ID: 23460714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
    Argiris A; Buchanan A; Brockstein B; Kolesar J; Ghebremichael M; Pins M; Hahn K; Axelrod R; Forastiere A
    Cancer; 2009 Oct; 115(19):4504-13. PubMed ID: 19634157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).
    Limaye S; Riley S; Zhao S; O'Neill A; Posner M; Adkins D; Jaffa Z; Clark J; Haddad R
    Oral Oncol; 2013 Aug; 49(8):835-41. PubMed ID: 23727257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
    Kushwaha VS; Gupta S; Husain N; Khan H; Negi MP; Jamal N; Ghatak A
    Cancer Biol Ther; 2015; 16(2):346-51. PubMed ID: 25756517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
    Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA;
    J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
    Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
    Mack PC; Holland WS; Burich RA; Sangha R; Solis LJ; Li Y; Beckett LA; Lara PN; Davies AM; Gandara DR
    J Thorac Oncol; 2009 Dec; 4(12):1466-72. PubMed ID: 19884861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
    Jimeno A; Bauman JE; Weissman C; Adkins D; Schnadig I; Beauregard P; Bowles DW; Spira A; Levy B; Seetharamu N; Hausman D; Walker L; Rudin CM; Shirai K
    Oral Oncol; 2015 Apr; 51(4):383-8. PubMed ID: 25593016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.
    Harari PM; Harris J; Kies MS; Myers JN; Jordan RC; Gillison ML; Foote RL; Machtay M; Rotman M; Khuntia D; Straube W; Zhang Q; Ang K
    J Clin Oncol; 2014 Aug; 32(23):2486-95. PubMed ID: 25002723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
    Burtness BA; Manola J; Axelrod R; Argiris A; Forastiere AA;
    Ann Oncol; 2008 May; 19(5):977-83. PubMed ID: 18296423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
    Jiang Y; Yuan Q; Fang Q
    J Cancer Res Clin Oncol; 2014 Jul; 140(7):1087-95. PubMed ID: 24728492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
    Bauman JE; Arias-Pulido H; Lee SJ; Fekrazad MH; Ozawa H; Fertig E; Howard J; Bishop J; Wang H; Olson GT; Spafford MJ; Jones DV; Chung CH
    Oral Oncol; 2013 May; 49(5):461-7. PubMed ID: 23384718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
    Ready N; Jänne PA; Bogart J; Dipetrillo T; Garst J; Graziano S; Gu L; Wang X; Green MR; Vokes EE;
    J Thorac Oncol; 2010 Sep; 5(9):1382-90. PubMed ID: 20686428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
    Price KA; Azzoli CG; Krug LM; Pietanza MC; Rizvi NA; Pao W; Kris MG; Riely GJ; Heelan RT; Arcila ME; Miller VA
    J Thorac Oncol; 2010 Oct; 5(10):1623-9. PubMed ID: 20871262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
    Caponigro F; Massa E; Manzione L; Rosati G; Biglietto M; De Lucia L; Sguotti C; Sganga P; Avallone A; Comella P; Mantovani G; Comella G
    Ann Oncol; 2001 Feb; 12(2):199-202. PubMed ID: 11300324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.